Trial · NCT03960541
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) | CD24Fc 240 mg | 6.24 | Standard Deviation 6.392 | Percent Change | |
| Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) | Placebo | 6.51 | Standard Deviation 19.690 | Percent Change | |
| Number of Participants With ≥1 Adverse Event (AE) | CD24Fc 240 mg | 4 | Participants | ||
| Number of Participants With ≥1 Adverse Event (AE) | Placebo | 4 | Participants | ||
| Number of Participants Who Withdrew From Study Treatment Due to an AE | CD24Fc 240 mg | 0 | Participants | ||
| Number of Participants Who Withdrew From Study Treatment Due to an AE | Placebo | 0 | Participants | ||
| Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein-Cholesterol (HDL-C), and Triglycerides | CD24Fc 240 mg | Percent Change from Baseline in Total Cholesterol at Week 6 | 4.66 | Standard Deviation 5.850 | Percent Change |
| Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein-Cholesterol (HDL-C), and Triglycerides | Placebo | Percent Change from Baseline in Total Cholesterol at Week 6 | 1.53 | Standard Deviation 10.947 | Percent Change |
| Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein-Cholesterol (HDL-C), and Triglycerides | CD24Fc 240 mg | Percent Change from Baseline in HDL-C at Week 6 | 6.69 | Standard Deviation 12.250 | Percent Change |
| Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein-Cholesterol (HDL-C), and Triglycerides | Placebo | Percent Change from Baseline in HDL-C at Week 6 | 0.88 | Standard Deviation 6.655 | Percent Change |
| Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein-Cholesterol (HDL-C), and Triglycerides | CD24Fc 240 mg | Percent Change from Baseline in Triglycerides at Week 6 | -8.42 | Standard Deviation 24.982 | Percent Change |
| Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein-Cholesterol (HDL-C), and Triglycerides | Placebo | Percent Change from Baseline in Triglycerides at Week 6 | -7.30 | Standard Deviation 23.607 | Percent Change |
| Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein-Cholesterol (HDL-C), and Triglycerides | CD24Fc 240 mg | Percent Change from Baseline in Total Cholesterol at Week 28 | 5.61 | Standard Deviation 21.672 | Percent Change |
| Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein-Cholesterol (HDL-C), and Triglycerides | Placebo | Percent Change from Baseline in Total Cholesterol at Week 28 | 2.40 | Standard Deviation 18.037 | Percent Change |
| Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein-Cholesterol (HDL-C), and Triglycerides | CD24Fc 240 mg | Percent Change from Baseline in HDL-C at Week 28 | 0.30 | Standard Deviation 0.610 | Percent Change |
| Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein-Cholesterol (HDL-C), and Triglycerides | Placebo | Percent Change from Baseline in HDL-C at Week 28 | 3.20 | Standard Deviation 19.512 | Percent Change |
| Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein-Cholesterol (HDL-C), and Triglycerides | CD24Fc 240 mg | Percent Change from Baseline in Triglycerides at Week 28 | -2.77 | Standard Deviation 48.320 | Percent Change |
| Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein-Cholesterol (HDL-C), and Triglycerides | Placebo | Percent Change from Baseline in Triglycerides at Week 28 | -1.80 | Standard Deviation 46.310 | Percent Change |
| Percent Change From Baseline in Cluster of Differentiation 4 (CD4)+ and Cluster of Differentiation 8 (CD8)+ T Cell Percentage | Group not reported | Percent Change from Baseline in CD4+ T Cell Percentage at Week 6 | |||
| Percent Change From Baseline in Cluster of Differentiation 4 (CD4)+ and Cluster of Differentiation 8 (CD8)+ T Cell Percentage | Group not reported | Percent Change from Baseline in CD4+ T Cell Percentage at Week 28 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03960541/results